U.S. markets close in 5 hours 33 minutes

  • S&P 500

    3,822.69
    -3.62 (-0.09%)
     

  • Dow 30

    30,591.85
    -95.63 (-0.31%)
     

  • Nasdaq

    13,600.36
    -12.42 (-0.09%)
     

  • Russell 2000

    2,150.23
    -1.21 (-0.06%)
     

  • Crude Oil

    56.02
    +1.26 (+2.30%)
     

  • Gold

    1,834.00
    +0.60 (+0.03%)
     

  • Silver

    26.89
    +0.49 (+1.85%)
     

  • EUR/USD

    1.2018
    -0.0030 (-0.25%)
     

  • 10-Yr Bond

    1.1250
    +0.0200 (+1.81%)
     

  • GBP/USD

    1.3649
    -0.0015 (-0.11%)
     

  • USD/JPY

    105.0500
    +0.0580 (+0.06%)
     

  • BTC-USD

    36,727.99
    +2,079.59 (+6.00%)
     

  • CMC Crypto 200

    746.46
    +3.46 (+0.47%)
     

  • FTSE 100

    6,497.91
    -18.74 (-0.29%)
     

  • Nikkei 225

    28,646.50
    +284.33 (+1.00%)
     

Borregaard ASA: Stock options exercised, repurchase of own shares

  • Oops!
    Something went wrong.
    Please try again later.
Borregaard
Updated ·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Today 10,000 stock options, granted under Borregaard’s option programme, were exercised at a strike price of NOK 94.06 per share.

In a related transaction, Borregaard repurchased 8,848 own shares at an average price of NOK 165.03 per share. The repurchase is conducted in accordance with a proxy given at the Ordinary General Meeting held on 15 June 2020.

After this transaction, the total number of options issued in Borregaard shares is 1,418,000. Borregaard owns 383,526 treasury shares representing 0.38% of total shares outstanding.

Borregaard ASA
Sarpsborg, 3 February 2021

Contact:
Lotte Kvinlaug, Investor Relations Officer, + 47 922 86 909

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.



Originally published

Latest Stories

  • ‘I was discarded after 40 years of marriage’: Can my ex-husband file a joint tax return without my consent? He tried to take both my stimulus checks

    My husband is intending to file a joint tax return, and told me straight out that he does not intend to give me any of our joint tax return, because he said that I am no longer working. Last year, while we were still married, he filed our joint return electronically against my wishes and without me knowing, and deposited the tax return in his bank account. Our divorce was finalized last November, so I no longer have access to his bank account.

  • A perfect storm is brewing for interest rates to surge, says this bond expert

    Scott Peng, the founder and chief investment officer of New York investment manager Advocate Capital Management, says a perfect storm is being unleashed.

  • Large Option Traders Making Aggressive Bets On GameStop, Nokia

    GameStop Corp. (NYSE: GME) shares fell 51.1% and Nokia (NYSE: NOK) shares tumbled 8% on Tuesday as the WallStreetBets-fueled short squeeze appears to be winding down for the time being. A flurry of large option trades in the two highly shorted stocks were mixed in nature on Tuesday as investors decide whether or not the short squeeze is over for good. The Trades: On Tuesday morning, Benzinga Pro subscribers received dozens of option alerts related to unusually large trades of GameStop and Nokia options. Here are a handful of the biggest: At 9:44 a.m., a trader bought 3,181 GameStop put options with a $75 strike price expiring on Friday at the ask price of $12.50. The trade represented a $3.97 million bearish bet. At 10:39 a.m., a trader bought 10,000 Nokia call options with a $5 strike price expiring in January 2023 at the ask price of $1.36. The trade represented a $1.36 million bullish bet. At 10:45 a.m, a trader sold 381 GameStop put options with a $200 strike price expiring on Friday near the bid price at $124. The trade represented a $4.72 million bullish bet. At 11:02 a.m., a trader bought another 10,000 Nokia call options with a $5 strike price expiring in January 2023 at the ask price of $1.40. The trade represented a $1.4 million bullish bet. Related Link: Why Short Sellers Help Keep The Stock Market In Check: 'Pricing Mechanism Is Broken' Without Them Why It's Important: Even traders who stick exclusively to stocks often monitor option market activity closely for unusually large trades. Given the relative complexity of the options market, large options traders are typically considered to be more sophisticated than the average stock trader. Many of these large options traders are wealthy individuals or institutions who may have unique information or theses related to the underlying stock. Unfortunately, stock traders often use the options market to hedge against their larger stock positions, and there’s no surefire way to determine if an options trade is a standalone position or a hedge. In this case, given the relatively small size of the largest PayPal trades by institutional standards, they were likely not institutional hedges. Short Squeeze Volatility: GameStop and Nokia are two of the popular stocks that WallStreetBets and other retail traders have targeted in recent weeks in triggering short squeezes in some of the most shorted stocks on Wall Street. In the past month, shares of Nokia spiked from under $4 to as high as $9.79 before dropping back down to around $4.50 on Tuesday. GameStop, which has the highest short percentage of float of any stock on the market, has been even more volatile. Shares skyrocketed from as low as $17.08 in January to new all-time highs of $483 this week before giving up a large chunk of those gains on Tuesday. GameStop shares were last trading at around $100. Even prior to the pandemic, both companies were struggling. In 2019, Nokia reported just $7 million in profits, its first positive net income since 2015. GameStop’s 2019 revenue was down 3% and it reported a net loss of $673 million. The WallStreetBets community helped drive a short squeeze in GameStop and other stocks that ultimately led to Robinhood and several other brokers limiting or banning buys of the most volatile stocks. The squeeze also hit hedge funds that were short GameStop and others extremely hard. Melvin Capital reported a 53% loss for the month of January and was forced to take $2.75 billion emergency investment from Citadel and Point72 Asset Management. Benzinga’s Take: The two largest GameStop option trades are short-term in nature, suggesting they are plays on the current short squeeze. The Nokia call purchases, on the other hand, don’t expire for nearly two years and maybe bets on the strength of the company’s underlying business. The $1.4 million Nokia call purchase has a break-even price of $6.40, suggesting at least 40.9% upside for the stock over the next two years. See more from BenzingaClick here for options trades from BenzingaWhy Short Sellers Help Keep The Stock Market In Check: 'Pricing Mechanism Is Broken' Without ThemHere's How Much Investing ,000 In Alibaba Stock 5 Years Ago Would Be Worth Today© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Sherwin-Williams sets 3-for-1 stock split

    Shares of Sherwin-Williams Co. were indicated up more than 1% in premarket trading Wednesday after the paints and coatings company said it will implement a three-for-one split of its common stock, effective April 1. The company said it was setting the stock split "to make the stock more accessible to employees and a broader base of investors." The stock split will be in the form of a stock dividend, payable March 31, with shareholders of record on March 23 receiving two additional common shares for each share they own. The stock closed Tuesday at $710.54, which would imply a post-split price of $236.85. The stock, which is still inactive in premarket trading, has rallied 23.6% over the past 12 months, while the S&P 500 has gained 17.8%.

  • Amazon CEO Jeff Bezos is stepping down — here's why Amazon stock isn't crashing

    Amazon founder and CEO Jeff Bezos is handing over the leadership reins to long-time right-hand man Andy Jassy. Here's why the stock isn't plunging.

  • Jazz Pharmaceuticals to Buy Pot-Drug Maker for $7.2 Billion

    (Bloomberg) -- Jazz Pharmaceuticals Plc has agreed to acquire GW Pharmaceuticals Plc, maker of the first drug derived from the cannabis plant to win approval in the U.S., for $7.2 billion in cash and stock.Under the terms of the proposed transaction, Jazz will pay $220 per GW American depositary receipt, in the form of $200 in cash and $20 in Jazz common stock, according to a statement from the companies.The price amounts to a premium of about 50% over Cambridge, England-based GW’s closing price on Tuesday. GW’s U.S.-traded shares gained as much as 49% in Wednesday trading, and Jazz shares rose as much as 6.1%.GW sells a medication called Epidiolex for children with severe epilepsy that was approved by the U.S. Food and Drug Administration in June 2018. The drug’s active compound, cannabidiol, produces an anticonvulsant effect through its interaction with prominent components of the nervous system. The plants from which the compound is drawn are bred to be low in THC, the chemical associated with getting high.GW is also in late-stage trials for another cannabis-based product to treat multiple sclerosis, and is working on candidates for autism and schizophrenia.Read More: Why the FDA Is High on a Marijuana Drug Made in EnglandJazz has an array of medications for cancer and other conditions and diseases, but is best known for its high-priced narcolepsy treatment Xyrem, which had sales of $1.64 billion in 2019. However, with the drug due to lose exclusivity soon, revenue from it was expected to peak at $1.75 billion in 2020, according to analyst estimates compiled by Bloomberg.The deal may lend further legitimacy to a growing segment of cannabis companies that focus on pharmaceutical-grade products. Such approaches are much safer in terms of regulatory risk, and allow the companies access to Europe’s markets. There, cannabis has so far been permitted mostly for medical, rather than recreational use.Acquiring GW “is an interesting strategic fit with Jazz’s neuroscience focus and adds a platform of innovative cannabinoid product candidates along with a highly specialized manufacturing expertise,” SVB Leerink analysts Ami Fadia and Eason Lee wrote in a note to clients Wednesday. They have an outperform rating on Jazz shares.GW’s rigorous approach to developing and producing its products has made the company a much-touted example of the potential for cannabis -- which many say is in the early stages of research and development for medical purposes despite its long history of recreational use.Growing IndustryThe deal also underlines a growing rift between companies that specialize in naturally versus synthetically derived cannabinoids.GW competes with a growing list of companies that expect that synthesizing derivatives from cannabis plants will be more useful to create predictable, pharmaceutical-grade ingredients, and bears less regulatory risk since there are no marijuana plants involved.Dealmaking is also picking up more broadly overall among cannabis companies that focus on medical and recreational use, as the industry anticipates regulatory headway in the U.S. under the new Democratic administration, and is widely expected to consolidate.Two of the biggest names in cannabis, Tilray Inc. and Aphria Inc., agreed in December to combine in a deal valued at about $3.8 billion.Industry experts have predicted that pharmaceutical giants and consumer goods companies might be more interested in making acquisitions in the sector if marijuana becomes legalized nationally in the U.S.The cash portion of the GW deal is expected to be funded with a combination of cash on hand and debt. Jazz, which has its corporate headquarters in Dublin, Ireland, had a market value of $8.7 billion as of the close of trading Tuesday. The proposed deal has been unanimously approved by the boards of both companies and is expected to close in the second quarter.(Updates share-price information in third paragraph and adds context throughout)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Taxes in retirement: What happens after your husband or wife dies

    One of the most common retirement tax planning errors I see is specific to married couples: not accounting for the tax changes that will occur once one of the two spouses dies. For example, using data from the SSA’s 2017 Period Life Table, we can calculate that, for a male/female couple both currently age 60 and in average health, there will be, on average, 11.3 years during which only one spouse is still alive. When one of the two spouses dies, there is generally a decrease in income, but it’s typically somewhat modest as a percentage of the household’s overall income — especially for retired couples who have managed to accumulate significant assets.

  • AT&T Stock: Is It A Buy Right Now? Here's What Earnings, Charts Show

    Despite being one of the most recognizable wireless carriers in the U.S., AT&T stock has had a rough 2020. But the stock does have some perks. Is it a buy?

  • Robinhood's future is 'toast,' says 'Wolf of Wall Street' Jordan Belfort

    Jordan Belfort, convicted felon and author of 'The Wolf of Wall Street,' has a warning for big money hedge funds and retail investors following the GameStop phenomenom.

  • Hedge-Fund Manager Ackman Raises Bet on Housing in Texas, Hawaii, Las Vegas

    Billionaire hedge-fund manager William Ackman is raising his bet that the migration of Americans to warmer, lower-tax cities is here to stay.

  • 3 ‘Strong Buy’ Stocks With 8% Dividend Yield

    Let’s talk portfolio defense. After last week’s social flash mob market manipulation, that’s a topic that should not be ignored. Now, this is not to say that the markets are collapsing. After 2% losses to close out last week’s Friday session, this week’s trading kicked off with a positive tone, as the S&P 500 rose 1.5% and the Nasdaq climbed 2.5%. The underlying bullish factors – a more stable political scene, steadily progressing COVID vaccination programs – are still in play, even if they are not quite as strong as investors had hoped. While increased volatility could stay with us for a while, it’s time to consider defensive stocks. And that will bring us to dividends. By providing a steady income stream, no matter what the market conditions, a reliable dividend stock provides a pad for your investment portfolio when the share stop appreciating. With this in mind, we’ve used the TipRanks database to pull up three dividend stocks yielding 8%. That’s not all they offer, however. Each of these stocks has scored enough praise from the Street to earn a “Strong Buy” consensus rating. New Residential Investment (NRZ) We’ll start by looking into the REIT sector, real estate investment trusts. These companies have long been known for dividends that are both high-yield and reliable – as a result of company compliance with tax rules, that require REITs to return a certain percentage of profits directly to shareholders. NRZ, a mid-size company with a market cap of $3.9 billion, holds a diverse portfolio of residential mortgages, original loans, and mortgage loan servicing rights. The company is based in New York City. NRZ holds a $20 billion investment portfolio, which has yielded $3.4 billion in dividends since the company’s inception. The portfolio has proven resilient in the face of the corona crisis, and after a difficult first quarter last year, NRZ saw rising gains in Q2 and Q3. The third quarter, the last reported, showed GAAP income of $77 million, or 19 cents per share. While down year-over-year, this EPS was a strong turnaround from the 21-cent loss reported in the prior quarter. The rising income has put NRZ in a position to increase the dividend. The Q3 payment was 15 cents per common share; the Q4 dividend was bumped up to 20 cents per common share. At this rate, the dividend annualizes to 80 cents and yields an impressive 8.5%. In another move to return profits to investors, the company announced in November that it had approved $100 million in stock repurchases. BTIG analyst Eric Hagen is impressed with New Residential – especially by the company’s sound balance sheet and liquidity. “[We] like the opportunity to potentially build some capital through retained earnings while maintaining a competitive payout. We think the dividend increase highlights the strengthening liquidity position the company sees itself having right now… we expect NRZ has been able to release capital as it's sourced roughly $1 billion of securitized debt for its MSR portfolio through two separate deals since September,” Hagen opined. In line with his comments, Hagen rates NRZ a Buy, and his $11 price target implies an upside of 17% for the year ahead. (To watch Hagen’s track record, click here) It’s not often that the analysts all agree on a stock, so when it does happen, take note. NRZ’s Strong Buy consensus rating is based on a unanimous 7 Buys. The stock’s $11.25 average price target suggests ~20% upside from the current share price of $9.44. (See NRZ stock analysis on TipRanks) Saratoga Investment Corporation (SAR) With the next stock, we move to the investment management sector. Saratoga specializes in mid-market debt, appreciation, and equity investments, and holds over $546 million in assets under management. Saratoga’s portfolio is wide ranging, and includes industrials, software, waste disposal, and home security, among others. Saratoga saw a slow – but steady – rebound from the corona crisis. The company’s revenues fell in 1Q20, and have been slowly increasing since. The fiscal Q3 report, released early in January, showed $14.3 million at the top line. In pre-tax adjusted terms, Saratoga’s net investment income of 50 cents per share beat the 47-cent forecast by 6%. They say that slow and steady wins the race, and Saratoga has shown investors a generally steady hand over the past year. The stock has rebounded 163% from its post-corona crash low last March. And the dividend, which the company cut back in CYQ2, has been raised twice since then. The current dividend, at 42 cents per common share, was declared last month for payment on February 10. The annualized payment of $1.68 gives a yield of 8.1%. Analyst Mickey Schleien, of Ladenburg Thalmann, takes a bullish view of Saratoga, writing, “We believe SAR's portfolio is relatively defensive with a focus on software, IT services, education services, and the CLO... SAR's CLO continues to be current and performing, and the company is seeking to refinance/upsize it which we believe could provide upside to our forecast." The analyst continued, "Our model anticipates SAR employing cash and SBA debentures to fund net portfolio growth. We believe the Board will continue to increase the dividend considering the portfolio's performance, the existence of undistributed taxable income, and the economic benefit of the Covid-19 vaccination program.” To this end, Schleien rates SAR a Buy along with a $25 price target. This figure implies a 20% upside from current levels. (To watch Schleien’s track record, click here) Wall Street’s analysts agree with Schleien on this stock – the 3 other reviews on record are Buys, and the analyst consensus rating is a Strong Buy. Saratoga’s shares are trading for $20.87, and carry an average price target of $25.50, suggesting an upside of 22% for the next 12 months. (See SAR stock analysis on TipRanks) Hercules Capital (HTGC) Last but not least is Hercules Capital, a venture capital company. Hercules offers financing support to small, early-stage client companies with scientific bent; Hercules’ clients are in life sciences, technology, and financial SaaS. Since getting started in 2003, Hercules has invested over $11 billion in more than 500 companies. The quality of Hercules’ portfolio is clear from the company’s recent performance. The stock has bounced back fully from the corona crisis of last winter, rebounding 140% from its low point reached last April. Earnings have also recovered; for the first nine months of 2020, HTGC posted net investment income of $115 million, or 11% higher than the same period of 2019. For dividend investors, the key point here is that the net investment income covered the distribution – in fact, it totaled 106% of the base distribution payout. The company was confident enough to boost the distribution with a 2-cent supplemental payment. The combined payout gives a $1.28 annualized payment per common share, and a yield of 8.7%. In another sign of confidence, Hercules completed a $100 million investment grade bond offering in November, raising capital for debt pay-downs, new investments, and corporate purposes. The bonds were offered in two tranches, each of $50 million, and the notes are due in March of 2026. Covering the stock for Piper Sandler, analyst Crispin Love sees plenty to love in HTGC. “We continue to believe that HTGC's focus on fast growing technology and life sciences companies sets the company up well in the current environment. In addition, Hercules is not dependent on a COVID recovery as it does not have investments in "at-risk" sectors. Hercules also has a strong liquidity position, which should allow the company to act quickly when it finds attractive investment opportunities,” Love commented. All of the above convinced Love to rate HTGC an Outperform (i.e. Buy). In addition to the call, he set a $16 price target, suggesting 9% upside potential. (To watch Love’s track record, click here) Recent share appreciation has pushed Hercules’ stock right up to the average price target of $15.21, leaving just ~4% upside from the trading price of $14.67. Wall Street doesn’t seem to mind, however, as the analyst consensus rating is a unanimous Strong Buy, based on 6 recent Buy-side reviews. (See HTGC stock analysis on TipRanks) To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Did You Score Big On GameStop Via Robinhood? How To Handle Your Capital Gains Tax . . . Or Capital Loss

    Investors on Robinhood and other sites scored big profits with bets on stocks like GameStop. Now they may owe hefty capital gains tax to the IRS.

  • Novavax Surges On Highly Effective Covid Shot; Is NVAX Stock A Buy?

    Novavax said in January its coronavirus vaccine was 89.3% effective in a Phase 3 test. It's also effective against the U.K. and South Africa variants. Is NVAX stock a buy?

  • AbbVie Stock: AbbVie Earnings Top Estimates, Guidance Strong

    AbbVie earnings and sales beat fourth-quarter estimates, with the pharmaceutical company guiding higher on 2021 EPS. AbbVie stock rose slightly.

  • Jazz Agrees To Buy Cannabis-Focused Biotech GW Pharma For $7.2 Billion

    Jazz Pharmaceuticals said Wednesday it will spend $7.2 billion to buy cannabis biotech GW Pharmaceuticals. In early action, GWPH stock soared.

  • 2 Biotech Stocks That Could Double in 2021; Canaccord Says ‘Buy’

    How can we know just where the markets are heading? The new year started with an upward trend that nearly got derailed by a flashmob from Reddit – and suddenly we’re dealing with a rise in volatility. Covering the markets for Canaccord, Chief Market Strategist Tony Dwyer believes that the "extraordinary liquidity from corporate bond and equity new issuance, an ultra-friendly Fed, and further fiscal stimulus suggests any weakness – even if sharp – should prove temporary and be used as opportunity to ramp risk exposure.” If Dwyer is right, then the key now is finding the best opportunities. Some of his colleagues at Canaccord are zeroing in on biotech stocks. These names offer investors a combination of high risk and high reward – if a new drug candidate should prove successful, the profit potential rise dramatically in a short time. Conversely, one mishap can send shares crashing. We’ve used the TipRanks database to pull up the details on two clinical-stage pharma companies that Canaccord’s analysts have tagged as likely winners – with the potential to double or more in value in the coming year. Cortexyme, Inc. (CRTX) The first Canaccord pick we’re looking at is Cortexyme, a clinical-stage drug developer researching treatments for degenerative diseases such as Alzheimer’s. The key point for investors in the Cortexyme story is the GAIN study. This is a Phase 2/3 study featuring drug candidate COR388, named atuzaginstat, a novel small-molecule lysine gingipain inhibitor, as a treatment for Alzheimer’s. The study follows 643 patients; the interim analysis, looking at the record of 300 of those patients, concluded in December with positive results, recommending that the full 1-year study continue as planned to final analysis. Investors, however, were hoping the trial would stop earlier for futility or overwhelming efficacy and, in reaction, sent the stock tumbling as news broke. Ahead of the top-line data read out, which is expected in 4Q21, Canaccord analyst Sumat Kulkarni believes that now is the time to pull the trigger. “Given the significant unmet need and market opportunity in AD, the final GAIN pivotal trial readout remains the most important 2021 event for CRTX that investors are tuned into... We continue to assume a 20% probability of approval for atuzaginstat and a 15% discount rate in our discounted cash flow (DCF) valuation... We assume a potential launch in 2025E and unadjusted peak sales of $9.1bn in 2031E," the 5-star analyst noted. To this end, Kulkarni rates CRTX a Buy, which is strongly supported by a $75 price target. This figure suggests a 108% upside in the coming year. (To watch Kulkarni’s track record, click here) Overall, over the past three months alone, "buy" ratings have outnumbered "sells" four-to-one on CRTX, and the average target price on Wall Street is $96. Assuming the analysts are right about that, investors in CRTX today stand to rake in ~166% profit over the next year. (See CRTX stock analysis on TipRanks) Black Diamond Therapeutics (BDTX) Next up, Black Diamond, is a drug company researching cancer treatments. Black Diamond focuses on genetically defined cancers with limited treatment options, and uses a proprietary tech platform, mutation-allostery-pharmacology, to develop small molecule therapies that will target specific mutations in a tumor agnostic manner. The company’s pipeline features two drug candidates at present, with the lead candidate, BDTX-189, in a Phase 1 study that is scheduled for completion in the first half of this year. BDTX-189 is showing promise in combatting allosteric EGFR and HER2 tumors, while minimizing potential toxic effects. That point could turn out to be key, as most current cancer treatments come with severe side effects. Black Diamond is continuing to enroll patients in the BDTX-189 study, in preparation for moving to Phase 2 later this year. The MasterKey-01 dose escalation study has progressed well, and defined a maximum tolerated dose within the company’s predictions. Covering BDTX for Canaccord, 5-star analyst Arlinda Lee noted, “We continue to expect first clinical data presentation data for lead MAP platform drug candidate BDTX-189, an inhibitor of allosteric ErbB mutations, at ASCO and initiation into Ph2 expansion cohorts mid-21. We view BDTX's unique approach of identifying allosteric driver mutations, targeting families of mutations with a single small molecule inhibitor, and tumor-agnostic development strategy as attractive." Given all of the above, Lee stays with the bulls. In addition to a Buy rating, the analyst puts a $50 price target on the stock. Investors could be pocketing a gain of 106%, should this target be met in the twelve months ahead. (To watch Lee’s track record, click here) Wall Street’s analysts can be a contentious lot – but when they agree on a stock, it’s a positive sign for investors to take note. That’s the case here, as all of the recent reviews on Black Diamond are Buy-side, making the consensus rating a unanimous Strong Buy. The analysts have given an average price target of $51.50, slightly more bullish than Lee’s above, and indicating a 112% upside from the current share price of $24.31. (See BDTX stock analysis on TipRanks) To find good ideas for biotech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Is PayPal Stock A Buy Right Now Before Earnings? Here's What Earnings, Charts Show

    Top digital payments stock PayPal is one of the leading growth stocks in the current stock market. But is it a buy right now?

  • Why Warren Buffett would never short GameStop — or any other stock

    Short selling has "ruined a lot of people," the Oracle of Omaha once said.

  • Here Are 6 Utility Stocks With Reliably Fast-Growing Dividends

    The utilities “almost universally have been getting good support from their regulators,” says John Bartlett, a portfolio manager at Reaves Asset Management. “Pretty much from every part of their financials, they’ve done just fine.”

  • Silver Plummets, and Gold Sells off Sharply Following the CME Margin Hike

    The precious metal complex (gold, silver, platinum, and palladium) traded under pressure, with all precious metal futures contracts closing sharply lower on the day.